Type 2 diabetes
Type 2 diabetes accounts for nearly 90% of the approximately 537 million cases of diabetes
worldwide. The number affected is increasing rapidly with alarming trends in children and …
worldwide. The number affected is increasing rapidly with alarming trends in children and …
Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study …
MJ Davies, VR Aroda, BS Collins, RA Gabbay… - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association and the European Association for the Study of Diabetes
convened a panel to update the previous consensus statements on the management of …
convened a panel to update the previous consensus statements on the management of …
Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the …
Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the previous consensus statements on the …
Diabetes convened a panel to update the previous consensus statements on the …
All‐cause mortality and cardiovascular outcomes with sodium‐glucose Co‐transporter 2 inhibitors, glucagon‐like peptide‐1 receptor agonists and with combination …
DR Riley, H Essa, P Austin, F Preston… - Diabetes, Obesity …, 2023 - Wiley Online Library
Aim To assess the relationship of sodium‐glucose cotransporter‐2 inhibitors (SGLT2i),
glucagon‐like peptide‐1 receptor analogues (GLP‐1RA) and their combination (SGLT2i+ …
glucagon‐like peptide‐1 receptor analogues (GLP‐1RA) and their combination (SGLT2i+ …
Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus …
Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough …
Glucometabolic outcomes of GLP-1 receptor agonist-based therapies in patients with type 2 diabetes: a systematic review and network meta-analysis
I Caruso, L Di Gioia, S Di Molfetta, A Cignarelli… - …, 2023 - thelancet.com
Background Innovative GLP-1 receptor agonist (GLP-1RA)-based treatment strategies—
such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA …
such as tirzepatide, GLP-1RA plus basal insulin fixed-ratio combinations [FRC], GLP-1RA …
[HTML][HTML] Advances in the management of type 2 diabetes in adults
RJ Galindo, JM Trujillo, CCL Wang, RG McCoy - BMJ medicine, 2023 - ncbi.nlm.nih.gov
Type 2 diabetes is a chronic and progressive cardiometabolic disorder that affects more than
10% of adults worldwide and is a major cause of morbidity, mortality, disability, and high …
10% of adults worldwide and is a major cause of morbidity, mortality, disability, and high …
Patient preferences for anti-hyperglycaemic medication for type 2 diabetes mellitus in China: findings from a national survey
S Liu, J Liu, L Si, X Ke, L Liu, Y Ren, S Bao, F Li… - BMJ Global …, 2023 - gh.bmj.com
Objective This study aimed to investigate the preferences regarding risks, benefits and other
treatment attributes of patients with type 2 diabetes mellitus (T2DM) in China when selecting …
treatment attributes of patients with type 2 diabetes mellitus (T2DM) in China when selecting …
The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review
AJ Scheen - Expert Review of Endocrinology & Metabolism, 2023 - Taylor & Francis
Introduction Sodium-glucose cotransporter 2 inhibitors (SGLT2is, gliflozins), the most recent
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …
oral antihyperglycaemic agents, provide a cardiorenal protection, an effect independent of …
Novel antidiabetic agents and their effects on lipid profile: A single shot for several cardiovascular targets
F Piccirillo, S Mastroberardino, A Nusca, L Frau… - International Journal of …, 2023 - mdpi.com
Type-2 diabetes mellitus (DM) represents one of the most important risk factors for
cardiovascular diseases (CVD). Hyperglycemia and glycemic variability are not the only …
cardiovascular diseases (CVD). Hyperglycemia and glycemic variability are not the only …